This program has concluded; please see this page for information on our upcoming conferences.
The following start-up companies presented at DUBLIN 2016, held April 12-14, 2016 at the Shelbourne Dublin, A Renaissance Hotel, Dublin, Ireland.
Acarix’s CADScor® System provides an acoustic detection of turbulent arterial flow and advanced algorithms to non-invasively rule out presence of Coronary Artery Disease (CAD) in symptomatic patients.
Aleva Neurotherapeutics has developed proprietary Neuromodulation technology that enables significantly better therapies for neurological diseases.
Anaconda BioMed holds a patent for a revolutionary device for the Acute Ischemic Stroke treatment. The ANCD Brain Advanced Thrombectomy Device is a distal access stented catheter that uses a disruptive technology in order to extract clots from the cerebral arteries.
Arterius Ltd. is developing a next-generation bioresorbable cardiovascular scaffold (stent), “ArterioSorb™, ” with an emerging market-leading clinical profile, intended to match the ease of delivery of bare metal stents (BMS) and drug-eluting stents (DES).
Biosensia’s RapiPlex is a point-of-care diagnosis system based on a set of proprietary technologies capable of producing quantitative and qualitative laboratory quality test results.
CereVasc is developing the eShunt™ System, a minimally-invasive, endovascular, cerebrospinal fluid shunt and delivery device intended to treat communicating hydrocephalus including NPH.
CorWave is developing the next generation of Left Ventricular Assist Devices (LVADs) for patients with chronic heart failure. Current LVAD technologies are turbine pumps that create non-physiologic conditions causing frequent adverse events, limitations in quality of life and resulting in poor economics.
Computational Signal Detection Laboratories (CSD Labs®) develops high-end medical software using state of the art engineering approaches in combination with in-house pioneering research. Specialized in the analysis and classification of complex data, CSD Labs offers clinically verified medical software for the objective, automated detection of heart defects. eMurmur is a clinically validated medical software for the objective, automated detection and documentation of heart defects during auscultation.
CVRx, Inc. is a privately held company founded in 2001 and headquartered in Minneapolis, Minnesota. The company has developed the second-generation Barostim neo, a minimally-invasive implantable system and the only device CE Marked for the separate indications of heart failure and resistant hypertension. Barostim neo is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure and hypertension in the United States. It is now MR Conditional, or safe for use under specified conditions in Europe. The company’s previous device, Barostim neo legacy™, holds Humanitarian Device Exemption (HDE) approval from the FDA, deeming it safe for use in patients who were responders to the first-generation Barostim Therapy with Rheos Carotid Sinus Lead System.
Daidalos Solutions is developing its unique patented Sutureless Clamp Valve technology applicable for surgical and catheter use with biological and mechanical valve prostheses in all anatomical heart valve positions, including mitral and tricuspid valves.
Echelon-Frontier Scientific innovates assay development for diagnostics and drug screening; biological sensor chemistry; light re/active-blocking compounds; and tumor imaging.
e-Matrix Innovations provides cutting-edge Artificial Intelligence solutions that learns from medical samples and structures to continuously improve the results of image analysis applicable in the medical industry. Application of the solution has already been implemented on wound analysis and the company is looking for further funding to expand into additional areas of application like that of blood analysis significantly reducing time and costs in providing high quality reliable results.
EMTensor GmbH is a medical device Company focused on R&D and commercialization of electromagnetic tomographic imaging technology and products for biomedical use. The company addresses the growing demand for cost effective, safe, and mobile imaging technologies needed for a wide range of medical applications such as detection of stroke and traumatic brain injuries, cardiovascular applications, imaging of various types of cancer and body injuries.
Glucorecs aims to help patients managing Diabetes and related conditions. Using patented RF technology, Glucorecs has non-invasive blood glucose measurement sensor technology for mobile, tabletop and wearable applications.
GlySure Ltd. has developed the GlySure TM system, a safe, accurate, easy-to-use continuous glucose monitoring (CGM) solution for critical care that is essential to optimizing glycemic control. The GlySureTM System provides critical care clinicians with the real-time and trending data required to proactively maintain blood glucose levels within a prescribed target range and manage potential hypoglycemic or hyperglycemic events and glucose variability.
Medicine today is characterized by clinicians looking retrospectively at diagnostic imaging and laboratory data, which results in expensive, reactionary procedures. GraftWorx is turning the Internet of Things into the Internet of the Body by enabling current “dumb” cardiovascular implants to become “smart.” We then leverage our cloud platform to alert clinicians of potential disasters. Our first product (currently in pre-clinical trials) will save 40,000 amputations in the US each year.
HemoSonics – Bringing to market a next-generation point-of-care diagnostic platform, the Quantra™, that provides actionable information to guide the management of critical bleeding and clotting.
Innoblative Designs, Inc. is a medical device company dedicated to commercializing radiofrequency ablation (RFA) probes that allow surgeons to intra-operatively destroy residual cancer that remains after the removal of a tumor (lumpectomy), thus reducing or eliminating the need for reoperations and dangerous, lengthy, expensive ionizing radiation therapy (RT).
Instent develops a breakthrough remote and non-invasive monitoring technology (patent pending) that can turn implantable medical devices into connected healthcare devices informing physicians about the characteristics of the tissue surrounding the device.
iSTAR Medical aims to improve the lives of patients suffering from eye diseases by developing innovative ophthalmic implants made from STAR® Biomaterial.
Joysys develops technologies that are evaluated in numerous scientific projects to meet the needs of experts and consumers in the healthcare sector. Joysys is a company that develops and markets technologies for health assessment and control.
Levita Magnetics is developing an innovative magnetic-robotic surgical platform, designed to evolve minimally invasive procedures.
Life Care Medical Devices (LCMD) is a medical device company focused on the production and distribution of technologies and products addressing unmet needs. The company’s lead product candidate, LapCapR 2.0 (formerly Keyhole CupR) is an innovative, proprietary device developed to advance the standard of care for laparoscopic surgery access. LCMD is dedicated to making surgery safer by working to ensure LapCapR becomes the global standard for laparoscopic access.
Lungpacer Medical is developing a catheter-based neurostimulation system designed to maintain diaphragm muscle strength and reduce lung injury for mechanically ventilated critical care patients.
Mainstay Medical International plc (“Mainstay”) is a medical device company which is developing an innovative implantable neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP).
Medexter Healthcare develops and markets a range of innovative software solutions that provide clinicians and medical personnel with highly efficient, patient-specific medical-knowledge-based support in their daily decision-making processes.
MicroOptx Medical is an early-stage medical device company that leverages academic bioengineering, surgical expertise, micro engineering manufacturing and nano technology to provide the modern solution for the vexing problem of glaucoma.
The NeuroTronik Neuromodulation System™, in development, is a novel medical technology approach to help physicians treat heart failure patients who come to the hospital because of their worsened symptoms.
Omixon is a global molecular diagnostics company, empowering clinical labs with technologies to improve patient outcomes by commercializing disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS).
Oval Medical Technologies is a privately funded, commercially focused emerging drug delivery technology company, dedicated to bringing a fundamentally different approach to the design of auto-injectors. Many aspects of the company’s device can be customized for highly viscous formulations or for particular patient populations, including those with severe dexterity problems. The technology platforms allow smaller and more flexible auto-injectors which have been shown, in many studies, to be preferred by patients and lead to fewer user errors.
Photo Dynamic Therapy (PDT) markets in INTERVENTIONAL ONCOLOGY their proprietary, CE-certified Application Support. Safe and effective by reactive O2 with significant survival, QoL and reimbursed in major markets.
Pristine Surgical has developed a breakthrough in rigid endoscopic technology which has the potential to improve over 20 million arthroscopic and laparoscopic surgical procedures worldwide per year. The company’s flagship product, the Giteliscope (named after the company’s founder, Dr. Michael Gitelis), provides surgeons with a fully-integrated imaging system and a clear, 180° pannable field of view in a sterile, single-use arthroscopic device. Pristine Surgical works in partnership with DEKA Research & Development Corp., is supported by world-class surgeons, and has a strong intellectual property position.
Quanta Fluid Solutions has developed advanced haemodialysis systems for use in the home and clinic. Our proprietary cartridge-based system SC+ is a portable, compact haemodialysis system providing clinical efficacy utilising flow rates typically used on traditional machines.
Quantason has developed a revolutionary, next-generation bi-modal (US/IDUS™) platform technology which fundamentally changes the utilization of conventional ultrasound both as a modality for diagnostic imaging and as an active screening method.
Seiratherm is marketing innovative devices in the area of TTM (targeted temperature management).
Sequana Medical – A Swiss medical device company dedicated to improving patient lives and reducing healthcare costs by developing innovative implantable pump systems to manage fluid balance within the body.
Sirius XT has developed a benchtop, soft x-ray microscope that produces fast, high resolution, high contrast, 3D images of the internal structure of whole biological cells.
Taragenyx is an orthopaedic biotechnology company developing self-healing implant technologies that help the body repair itself. Our proprietary device-drug combination therapies deliver medications directly to the implant site to improve fixation, prevent infection, and help patients heal faster in far less pain.
Velico Medical is a private, pre-clinical medical technology company focused on applying proprietary technologies to improve the quality, availability and economics of platelets and plasma (human blood components) for transfusion.
X-Bolt Orthopaedics, “The Hip Fracture Fixation Company,” is combining simple techniques and concise inventory with innovative design features with strong bone fixation to result in a near-zero reoperation rate in the high volume market of hip fracture fixation.
Xeltis is a European medical device company dedicated to transforming the standards of care in cardiac valve replacement and vascular intervention. Xeltis is developing the first-ever bioabsorbable cardiovascular valves and vessels designed to allow Endogenous Tissue Restoration (ETR), a new transformational therapeutic approach in cardiovascular treatment.